Patents by Inventor Mikhail L. Gishizky

Mikhail L. Gishizky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF
    Publication number: 20110159532
    Abstract: The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.
    Type: Application
    Filed: November 30, 2010
    Publication date: June 30, 2011
    Applicant: SUGEN, INC.
    Inventors: Tod R. Smeal, Marinella G. Callow, Bahija Jallal, Sergey Zozulya, Mikhail L. Gishizky
  • GEF-H1b: biomarkers, complexes, assays and therapeutic uses thereof
    Patent number: 7871786
    Abstract: The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: January 18, 2011
    Assignee: Sugen, Inc.
    Inventors: Tod R. Smeal, Marinella G. Callow, Bahija Jallal, Sergey Zozulya, Mikhail L. Gishizky
  • GEF-H1b: biomarkers, complexes, assays and therapeutic uses thereof
    Publication number: 20090130695
    Abstract: The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.
    Type: Application
    Filed: September 11, 2008
    Publication date: May 21, 2009
    Inventors: Tod R. Smeal, Marinella G. Callow, Bahija Jallal, Sergey Zozulya, Mikhail L. Gishizky
  • GEF-H1b: biomarkers, complexes assays and therapeutic uses thereof
    Patent number: 7439329
    Abstract: The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: October 21, 2008
    Assignee: Sugen, Inc.
    Inventors: Tod R. Smeal, Marinella G. Callow, Bahija Jallal, Sergey Zozulya, Mikhail L. Gishizky
  • GEF-H1b: biomarkers, complexes assays and therapeutic uses thereof
    Publication number: 20040091907
    Abstract: The present invention relates to diagnosing abnormal cell proliferation in biological samples and screening for drugs which inhibit, reduce or abolish cell growth, especially tumorigenic cell growth, by detecting a phosphovariant isoform of a guanine nucleotide exchange factor biomarker, such as the novel GEF-H1S.
    Type: Application
    Filed: July 2, 2003
    Publication date: May 13, 2004
    Applicant: Sugen, Inc.
    Inventors: Tod R. Smeal, Marinella G. Callow, Bahija Jallal, Sergey Zozulya, Mikhail L. Gishizky
  • Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
    Publication number: 20030092079
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of cell proliferative disorders wherein a protein tyrosine kinase or protein tyrosine phosphatase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins is involved. This invention is based, in part, on the surprising discovery that the adaptor protein, GRB-2, binds the intracellular BCR-ABL tyrosine kinase product in vivo and is necessary for the activation of the oncogenic potential of the BCR/ABL product. The present invention further relates to protein tyrosine kinase/adaptor protein complexes and the uses of these complexes for the identification of agents capable of decreasing or inhibiting the interaction between the members of such complexes.
    Type: Application
    Filed: July 12, 2002
    Publication date: May 15, 2003
    Applicant: New York University/Duke University/Sugen Inc.
    Inventors: Joseph Schlessinger, Mikhail L. Gishizky, Ann Marie Pendergast
  • Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
    Patent number: 6528270
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of cell proliferative disorders wherein a protein tyrosine kinase or protein tyrosine phosphatase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins is involved. This invention is based, in part, on the surprising discovery that the adaptor protein, GRB-2, binds the intracellular BCR-ABL tyrosine kinase product in vivo and is necessary for the activation of the oncogenic potential of the BCR/ABL product. The present invention further relates to protein tyrosine kinase/adaptor protein complexes and the uses of these complexes for the identification of agents capable of decreasing or inhibiting the interaction between the members of such complexes.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: March 4, 2003
    Assignees: Sugen, Inc., Duke University, New York University
    Inventors: Joseph Schlessinger, Mikhail L. Gishizky, Ann Marie Pendergast
  • Method and compositions for treatment of BCR-ABL associated leukemias and other cell proliferative disorders
    Patent number: 6066463
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of cell proliferative disorders wherein a protein tyrosine kinase or protein tyrosine phosphatase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins is involved. This invention is based, in part, on the surprising discovery that the adaptor protein, GRB-2, binds the intracellular BCR-ABL tyrosine kinase product in vivo and is necessary for the activation of the oncogenic potential of the BCR/ABL product. The present invention further relates to protein tyrosine kinase/adaptor protein complexes and the uses of these complexes for the identification of agents capable of decreasing or inhibiting the interaction between the members of such complexes.
    Type: Grant
    Filed: May 20, 1994
    Date of Patent: May 23, 2000
    Assignees: New York University, Duke University, Sugen, Inc.
    Inventors: Joseph Schlessinger, Mikhail L. Gishizky, Ann Marie Pendergast